share_log

Deutsche Bank Initiates Coverage On Immunovant With Buy Rating, Announces Price Target of $50

Benzinga ·  Dec 12, 2023 05:11

Deutsche Bank analyst Neena Bitritto-Garg initiates coverage on Immunovant (NASDAQ:IMVT) with a Buy rating and announces Price Target of $50.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment